Pharmaceutical Industry in
Eysins

AliveDx Suisse SA

Since 2013 · 101–500 empl.·5.0(3)

The core activity of AliveDx is the development and manufacture of innovative solutions for clinical diagnostics, particularly in the field of blood banks and automated testing platforms. The company focuses on creating products that make laboratory work more efficient and improve decision-making in clinical practice. The main products include the blood bank reagent portfolio 'Alba' and the automated testing platform 'MosaiQ'.

Matrixsanos Sàrl

Since 1996 · 1–10 empl.

Matrixsanos Sàrl manufactures chromopuncture instruments, ultrasonic devices to deter martens, and instruments for producing silver and copper colloids. The company supplies specialized products for therapists and for personal use.

Merck Performance Materials (Suisse) SA

Since 2003 · 101–500 empl.

Merck Performance Materials (Suisse) SA is part of the Merck Group and operates in Switzerland across the Healthcare, Life Science and Electronics businesses. The company develops and supplies products, technologies and services for research, medical applications, and electronics and semiconductor uses.

Asceneuron SA

Since 2012 · 11–20 empl.

The core activity of Asceneuron SA is the development of innovative small molecules and Tau modifiers for the treatment of diseases, particularly in the area of the central nervous system (CNS). The company focuses on the early stages of drug development and conducts clinical trials to test the efficacy and safety of its active ingredients.

Fresenius Kabi SwissBioSim GmbH

Since 2017 · 1–10 empl.

Fresenius Kabi SwissBioSim GmbH belongs to the Fresenius Kabi group and operates in healthcare. The company provides medicines, infusion therapy, medical nutrition, MedTech solutions and biopharmaceuticals for the care of critically and chronically ill patients.

Pharmotech SA

Since 2018 · 1–10 empl.

The core activity of Pharmotech SA is the research and development of medical products based on plant-based active ingredients, particularly CBD, to combat multi-resistant bacteria (MDR-MRSA). The company focuses on researching and developing innovative solutions to combat bacteria such as Pseudomonas Aeruginosa and Staphylococcus Aureus.

Chord Therapeutics SA

Since 2014 · 1–10 empl.

Augusta Life Sciences SwissCo Sàrl

Since 2025 · 1–10 empl.

Augusta Life Sciences SwissCo Sàrl is listed by Waters as one of the acquired entities in its life sciences and diagnostics business combination. The company appears on Waters’ website in the context of the transaction summary and subsidiary structure.